• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • COVID-19
  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • Artificial Intelligence
    • Blockchain
    • Mobile Health
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

Affect Therapeutics Secures $16M to Expand App for Drug and Alcohol Addiction

by Fred Pennic 07/12/2023 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print
Affect Therapeutics Secures $16M to Expand App for Drug and Alcohol Addiction

What You Should Know: 

  • Today, Affect Therapeutics – a McLean, VA-based company reimagining alcohol and drug addiction treatment with smartphone apps that put an integrated treatment program into the pocket of its members raises $16M in Series A funding led by ARTIS Ventures. The funding also included additional participation from previous investors AlleyCorp and CityLight, as well as new investments from LifeArc Ventures, Samsung Next, and What If Ventures. 
  • Founded in 2020, Affect Therapeutics offers clinically intensive treatment that is all-digital, accessible, and cost-effective.

Supporting Entire Recovery Journey

Affect has established a scientifically-proven program that supports the entire recovery journey, and is the first company to reward healthy behavior with financial incentives, known as contingency management, to drive motivation resulting in increased retention and more durable sobriety. This is coupled with counseling, medical oversight, and case management, delivering a comprehensive program based on decades of research. Affect has already treated thousands of patients with results that are proven to be twice as effective as traditional treatment models by key metrics insurance and medical partners value most. More importantly, these outcomes change peoples’ lives and lead them to manage the chronic disease of addiction into lasting remission.

In its short time in market, Affect has already treated thousands of patients with results that are proven to be twice as effective as traditional treatment models by key metrics insurance and medical partners value most. More importantly, these outcomes change peoples’ lives and lead them to manage the chronic disease of addiction into lasting remission. 

Availability

Affect currently holds outpatient treatment licenses in 20 states and aims to serve a majority of the U.S. population by the end of 2023. The company partners with the largest health insurance payers in the country, including UnitedHealthcare, Aetna, Humana, Molina, and Centene. The company plans to use the funding to advance their program initiatives in more states, as well as engineering innovation in its platform. The Affect app is free to download on the Google Play Store or Apple App Store.

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Behavioral Health

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Knowledge Hub

 How Top Health Plans Use AI to Save Money and Work Smarter How Top Health Plans Use AI to Save Money and Work Smarter

 How to Build Hybrid Care Models Around Remote Patient Monitoring How to Build Hybrid Care Models Around Remote Patient Monitoring

Trending

Olive Secures $400M At A $4B Valuation to Support New Instant Claim Payment Solution

Olive Shutters Business After Sale to Waystar and Humata Health

Clinician Shortage Worsens Primary Care Crisis, Experts Reveal

Clinician Shortage Worsens Primary Care Crisis, Experts Reveal

FDA Grants Clearance for UltraSight's AI Cardiac Ultrasound

Israel Defense Forces to Utilize UltraSight’s PoCUS Devices in Combat

The Future of Biomarker-Based Therapy for Mental Disorder Care

The Future of Biomarker-Based Therapy for Mental Disorder Care

HLTH23: 6 Digital Health Executives Share Key Takeaways

6 Digital Health Executives Share Key Takeaways from HLTH23

HIMSS Appoints New Chief Financial Officer & General Counsel

HIMSS Appoints New Chief Financial Officer & General Counsel

GoodRx Now Offers Access to $35 Insulin to All Americans

GoodRx Now Offers Access to $35 Insulin to All Americans

Ozempic: From Diabetes Management to Potential Weight Loss Miracle

Ozempic: From Diabetes Management to Potential Weight Loss Miracle

Health M&A: Financial Distress Driving Q3 Healthcare Deals

Health M&A: Financial Distress Driving Q3 Healthcare Deals

GE HealthCare Inks $44M Contract with BARDA to Develop AI-Driven Ultrasound Tech

GE HealthCare Inks $44M Contract with BARDA to Develop AI-Driven Ultrasound Tech

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • 2023 Editorial Calendar
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2023. HIT Consultant Media. All Rights Reserved. Privacy Policy |